ASMB - Assembly Biosciences Inc Stock Price, Fair Value and News

13.21USD+0.74 (+5.93%)Market Closed

Market Summary

USD13.21+0.74

Market Closed

5.93%

ASMB Stock Price

View Fullscreen

ASMB RSI Chart

ASMB Valuation

Market Cap

72.4M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

10.11

EV/EBITDA

-0.87

Price/Free Cashflow

3.22

ASMB Price/Sales (Trailing)

ASMB Profitability

EBT Margin

-854.32%

Return on Equity

-148.98%

Return on Assets

-44.75%

Free Cashflow Yield

31.05%

ASMB Fundamentals

ASMB Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

1.1K%

Rev. Growth (Qtr)

749.36%

ASMB Earnings

Earnings (TTM)

-61.2M

Earnings Growth (Yr)

51.05%

Earnings Growth (Qtr)

23.98%

Breaking Down ASMB Revenue

Last 7 days

-8.1%

Last 30 days

-8.3%

Last 90 days

8.1%

Trailing 12 Months

-1.4%

How does ASMB drawdown profile look like?

ASMB Financial Health

Current Ratio

3.41

ASMB Investor Care

Shares Dilution (1Y)

26.49%

Diluted EPS (TTM)

-13.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	7.0M	7.2M
2022	6.4M	0	6.6M	6.8M
2021	54.8M	0	30.5M	6.3M
2020	16.2M	52.5M	82.8M	79.1M
2019	15.1M	15.0M	14.9M	16.0M
2018	11.9M	12.8M	14.4M	14.8M
2017	3.0M	6.0M	7.5M	9.0M
2016	1.7M	1.9M	1.8M	1.5M
2015	185.7K	360.0K	827.5K	1.2M
2014	192.7K	184.3K	176.0K	167.7K
2013	0	0	0	201.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Assembly Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	okazaki jason a	sold	-4,627	13.0719	-354	ceo and president
Apr 01, 2024	mchutchison john g	sold	-15,764	13.0719	-1,206	-
Apr 01, 2024	bjorkquist jeanette m	sold	-1,490	13.0719	-114	principal accounting officer
Apr 01, 2024	white nicole s	sold	-2,575	13.0719	-197	chief manufacturing officer
Mar 29, 2024	bjorkquist jeanette m	acquired	-	-	850	principal accounting officer
Mar 27, 2024	okazaki jason a	sold	-5,045	12.87	-392	ceo and president
Jan 18, 2024	schornstein alexander	bought	276,069	0.8	345,086	-
Jan 17, 2024	schornstein alexander	bought	235,195	0.784	299,994	-
Nov 21, 2023	schornstein alexander	bought	66,700	0.667	100,000	-
Nov 20, 2023	schornstein alexander	bought	215,400	0.718	300,000	-

Which funds bought or sold ASMB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	sold off	-100	-14,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-13,012	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-	-	-%
Apr 15, 2024	Palumbo Wealth Management LLC	sold off	-100	-8,263	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.42	-64,111	1,918,290	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-3,000	29,000	-%
Feb 15, 2024	Baker Avenue Asset Management, LP	sold off	-100	-885	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	36,821	36,821	-%
Feb 14, 2024	CITADEL ADVISORS LLC	reduced	-9.85	-20,187	102,442	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%

Are Funds Buying or Selling ASMB?

Are funds buying ASMB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ASMB

No. of Funds

Unveiling Assembly Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 22, 2023	schornstein alexander	11.51%	7,564,292	SC 13D/A
Nov 03, 2023	schornstein alexander	10.9%	7,164,292	SC 13D/A
Oct 31, 2023	schornstein alexander	-	0	SC 13D
Oct 25, 2023	gilead sciences, inc.	19.9%	13,073,668	SC 13D
Feb 14, 2023	deep track capital, lp	3.76%	1,833,437	SC 13G/A
Feb 15, 2022	armistice capital, llc	4.2%	2e+06	SC 13G/A
Feb 14, 2022	consonance capital management lp	-	0	SC 13G/A
Feb 14, 2022	deep track capital, lp	6.27%	3e+06	SC 13G/A
Feb 09, 2022	vanguard group inc	4.61%	2,205,053	SC 13G/A
Oct 12, 2021	deep track capital, lp	5.32%	2,393,876	SC 13G

Recent SEC filings of Assembly Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	DEFA14A	DEFA14A
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	ARS	ARS
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 29, 2024	4	Insider Trading
Mar 28, 2024	8-K	Current Report

Peers (Alternatives to Assembly Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	3.52%	-17.31%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-3.68%	-28.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-7.53%	-16.73%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-8.64%	-30.91%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-24.84%	-46.72%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-17.14%	78.66%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-20.91%	-36.67%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	-9.41%	-43.91%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-5.61%	336.79%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-17.51%	25.55%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-57.88%	56.88%	-0.24	2.14	-13.45%	66.37%

Assembly Biosciences Inc News

Latest updates

Assembly Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2022Q4	2022Q3	2022Q1	2021Q4	2021Q3	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	749.4%	5,334,000	628,000	442,000	256,000	128,000	-	6,254,000	3,645,500	1,037,000	34,611,000	39,376,000	4,081,000	4,767,000	4,231,000	3,080,000	3,885,000	3,735,000	4,286,000	3,218,000	3,565,000	3,315,000
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	26,861,411	30,383,786	20,237,209	-
Operating Expenses	31.0%	19,714,000	15,048,000	22,978,000	23,401,000	23,162,000	62,889,000	25,129,000	27,258,000	40,679,000	38,630,000	32,797,000	31,775,000	33,451,000	30,224,000	22,780,000	32,221,000	30,057,000	26,861,000	30,384,000	20,237,000	-
S&GA Expenses	106.2%	8,708,000	4,224,000	6,125,000	5,271,000	5,957,000	6,504,000	6,655,000	8,704,000	7,170,000	11,689,000	9,470,000	8,729,000	10,834,000	8,488,000	4,080,000	9,517,000	8,806,000	7,752,000	12,544,000	5,696,000	-
R&D Expenses	1.7%	11,006,000	10,824,000	16,853,000	18,130,000	17,205,000	14,747,000	18,474,000	18,554,000	33,509,000	26,941,000	23,327,000	23,046,000	22,616,500	21,736,000	18,700,000	22,704,000	21,251,000	19,109,000	17,840,000	14,541,000	-
EBITDA Margin	81.2%	-8.48	-45.02	-90.54	-47.66	-29.23	-21.08	-2.01	-1.12	-0.78	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-741,000	-15,000	-11,000	-7,000	1,139,000	-6,000	-34,000	-	-8,944,584
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-39,418,000	-3,349,000	7,270,000	-26,655,000	-27,825,000	-25,010,000	-18,514,000	-27,059,000	-25,022,000	-21,541,000	-26,840,000	-16,249,000	-11,952,108
EBT Margin	81.1%	-8.54	-45.29	-91.09	-47.86	-29.35	-21.17	-2.04	-1.13	-0.79	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	24.0%	-10,962,000	-14,420,000	-22,395,000	-23,145,000	-23,091,000	-60,257,000	-18,803,000	-27,200,000	-39,418,000	-3,349,000	7,270,000	-26,655,000	-27,084,000	-24,995,000	-18,503,000	-27,052,000	-26,161,000	-21,535,000	-26,806,000	-16,249,000	-
Net Income Margin	75.8%	-8.55	-35.35	-91.09	-47.34	-27.88	-20.76	-3.57	-1.14	-0.79	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	626.1%	73,576,000	-13,984,000	-19,254,000	-19,924,000	-27,502,000	-19,380,000	-18,882,000	-36,422,000	-25,269,000	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	165.0%	137	52.00	67.00	83.00	102	122	143	163	191	249	262	279	283	306	295	313	340	223	242	259	268
Current Assets	169.3%	134	50.00	64.00	80.00	97.00	115	124	131	154	188	206	222	224	246	235	257	283	165	183	201	223
Cash Equivalents	-25.6%	20.00	27.00	22.00	43.00	52.00	55.00	43.00	51.00	46.00	71.00	60.00	78.00	59.00	58.00	97.00	42.00	47.00	25.00	34.00	29.00	41.00
Net PPE	-31.4%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00
Goodwill	-	-	-	-	-	-	-	-	-	-	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
Liabilities	865.5%	96.00	10.00	12.00	13.00	19.00	19.00	19.00	16.00	22.00	24.00	30.00	32.00	43.00	36.00	28.00	62.00	67.00	67.00	67.00	69.00	57.00
Current Liabilities	450.0%	39.00	7.00	9.00	10.00	16.00	15.00	15.00	11.00	16.00	15.00	14.00	14.00	24.00	17.00	17.00	21.00	24.00	21.00	20.00	25.00	18.00
Shareholder's Equity	-1.5%	41.00	42.00	55.00	70.00	83.00	102	124	147	169	225	232	247	241	271	267	252	273	156	175	190	211
Retained Earnings	-1.4%	-785	-774	-760	-743	-724	-702	-678	-654	-631	-571	-552	-528	-501	-462	-458	-466	-439	-412	-387	-368	-341
Additional Paid-In Capital	1.2%	827	817	816	814	808	805	804	802	801	796	784	776	742	733	726	718	713	569	562	559	553
Accumulated Depreciation	-	0.00	-	-	-	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	25.0%	5.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	60.00	-	-	-	101	-	-	-	168	-	-	-	757	-	-	-	333	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	631.8%	73,647	-13,848	-13,628	-23,428	-19,254	-19,822	-17,885	-27,502	-19,362	-18,882	-21,808	-33,344	-25,269	10,646	-23,116	-25,218	-20,528	-18,595	-21,005	-23,939	-16,727
Share Based Compensation	-15.5%	959	1,135	1,190	1,835	2,013	1,556	1,581	1,443	1,945	1,592	1,986	-286	3,747	6,048	7,134	4,924	6,509	5,404	2,068	6,577	6,807
Cashflow From Investing	-574.8%	-89,654	18,881	-8,365	10,000	16,562	31,432	9,597	33,049	-8,484	20,070	-3,087	18,016	20,715	-49,887	76,549	20,693	-95,022	7,819	25,450	11,435	-62,159
Cashflow From Financing	-	9,192	-	134	4,492	437	-	177	-	2,713	10,055	6,159	34,137	5,687	843	950	119	137,415	1,385	706	140	605

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ASMB Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Collaboration revenue ($4,430 and $- from a related party)	$ 7,163	$ 0
Operating expenses
Research and development	48,900	69,980
General and administrative	22,909	24,134
Total operating expenses	71,809	94,114
Loss from operations	(64,646)	(94,114)
Other income
Interest and other income, net	3,451	1,022
Total other income	3,451	1,022
Loss before income taxes	(61,195)	(93,092)
Income tax expense	(33)	0
Net loss	(61,228)	(93,092)
Other comprehensive loss
Unrealized gain (loss) on marketable securities	722	(384)
Comprehensive loss	$ (60,506)	$ (93,476)
Net loss per share - basic	$ (13.38)	$ (23.08)
Net loss per share - diluted	$ (13.38)	$ (23.08)
Weighted average common shares outstanding, basic	4,577,371	4,034,105
Weighted average common shares outstanding, diluted	4,577,371	4,034,105

ASMB Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 19,841	$ 52,418
Marketable securities	110,406	39,192
Accounts receivable from collaboration	43	944
Prepaid expenses and other current assets	3,497	4,413
Total current assets	133,787	96,967
Property and equipment, net	385	743
Operating lease right-of-use (ROU) assets	2,339	3,195
Other assets	312	889
Total assets	136,823	101,794
Current liabilities
Accounts payable	461	2,493
Accrued research and development expenses	885	3,122
Other accrued expenses	5,744	7,317
Deferred revenue - short-term ($30,915 and $- to a related party)	30,915
Operating lease liabilities - short-term	1,220	3,364
Total current liabilities	39,225	16,296
Deferred revenue - long-term ($55,379 and $- to a related party)	55,379	2,733
Operating lease liabilities - long-term	1,122	101
Total liabilities	95,726	19,130
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 5,482,752 and 4,074,552 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	5	4
Additional paid-in capital	826,921	807,983
Accumulated other comprehensive loss	(81)	(803)
Accumulated deficit	(785,748)	(724,520)
Total stockholders' equity	41,097	82,664
Total liabilities and stockholders' equity	$ 136,823	$ 101,794

About Assembly Biosciences Inc

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

CEO	Mr. Jason A. Okazaki
WEBSITE	assemblybio.com
INDUSTRY	Biotechnology
EMPLOYEES	70

Assembly Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Assembly Biosciences Inc? What does ASMB stand for in stocks?

ASMB is the stock ticker symbol of Assembly Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Assembly Biosciences Inc (ASMB)?

As of Tue Apr 30 2024, market cap of Assembly Biosciences Inc is 68.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers.

What is the fair value of ASMB stock?

You can check ASMB's fair value in chart for subscribers. The fair value of Assembly Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Assembly Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ASMB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Assembly Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ASMB is over valued or under valued. Whether Assembly Biosciences Inc is cheap or expensive depends on the assumptions which impact Assembly Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ASMB.

What is Assembly Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ASMB's PE ratio (Price to Earnings) is -1.12 and Price to Sales (PS) ratio is 9.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ASMB PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Assembly Biosciences Inc's stock?

In the past 10 years, Assembly Biosciences Inc has provided -0.153 (multiply by 100 for percentage) rate of return.